Filing Flows › Ocular Therapeutix (OCUL) › Q3 2026 › vs Q3 2025
Ocular Therapeutix (OCUL) Q3 2026 vs Q3 2025 (year over year)
Ocular Therapeutix's revenue fell $1.7M (-11%) from $14.5M in Q3 2025 to $12.9M in Q3 2026.
Ocular Therapeutix, Q3 2026: revenue $12.9M (-12% year over year), operating margin -760.1%, net loss $94.8M, operating cash flow −$65.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.9M | $14.5M | −$1.7M | -11% |
| Other income, net | $3.1M | −$720K | $3.8M | — |
| Net loss | $94.8M | $69.4M | $25.4M | +37% |
| Costs & expenses | $111M | $84.0M | $26.8M | +32% |
| Operating costs | $111M | $83.2M | $27.5M | +33% |
| Cost of revenue | $1.5M | $1.8M | −$319K | -18% |
| Research & development | $74.8M | $52.4M | $22.4M | +43% |
| Sales & marketing | $15.7M | $13.1M | $2.6M | +20% |
| General & admin | $18.8M | $16.0M | $2.8M | +18% |
| Operating cash sources | $94.8M | $69.4M | $25.4M | +37% |
| Depreciation & amortization | $2.4M | $1.1M | $1.4M | +127% |
| Share-based compensation | $15.1M | $11.7M | $3.4M | +29% |
| Working capital & other | $11.7M | $5.9M | $5.7M | +97% |
| Cash used in operations | $65.6M | $50.7M | $14.9M | +29% |
| Net loss absorbed | $94.8M | $69.4M | $25.4M | +37% |
Questions
How much did Ocular Therapeutix's revenue grow year over year in Q3 2026?
Ocular Therapeutix's revenue fell $1.7M (-11%) from $14.5M in Q3 2025 to $12.9M in Q3 2026.